RxDoctor Payments DataLook up a doctor →

Rocio Harbison, MD

Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1881710499

Payments from drug & device makers

$3,226,672in general payments, 2019–2025

Across 1,611 payments — averaging $2002.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.8M
  • Novo Nordisk$300K
  • Corcept Therapeutics$240K
  • Amgen$222K
  • Lilly USA, LLC$215K
  • AstraZeneca$138K
  • plus $345K from 53 others
$9,439in research payments, 2019–2025

Across 5 payments — averaging $1887.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$9K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly21$1,766,910
Novo Nordisk404$299,611
Corcept Therapeutics235$240,097
Amgen20$222,241
Lilly USA, LLC348$215,414
AstraZeneca(2 entities)89$137,838
Acella Pharmaceuticals, LLC12$116,787
Medtronic(2 entities)84$91,169
Esperion Therapeutics, Inc.54$34,051
Dexcom, Inc.56$32,429
Tandem Diabetes Care, Inc.81$27,870
AbbVie34$13,957
Avion Pharmaceuticals2$11,050
Ionis Pharmaceuticals, Inc.2$3,834
Sanofi-aventis U.S. LLC19$3,772
IBSA Pharma Inc.10$2,095
Modernatx, Inc.8$1,553
Companion Medical, Inc.9$1,477
Merck3$1,012
BETA Bionics, Inc.14$982
Bigfoot Biomedical Inc4$360
Boehringer Ingelheim9$215
Valeritas, Inc.4$204
Xeris Pharmaceuticals, Inc.8$153
Cequr Corporation1$116
Abbott6$109
Mannkind Corporation3$92
Insulet Corporation5$84
Radius Health, Inc.4$84
Amarin Pharma, Inc.4$79
Antares Pharma, Inc.4$73
Shire North American Group Inc3$66
Ascendis Pharma Endocrinology Inc3$63
Astellas Pharma US Inc3$62
Amneal Pharmaceuticals LLC4$60
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$59
Madrigal Pharmaceuticals2$49
Avvisto Therapeutics, LLC1$45
Recordati_rare_diseases_inc.2$44
Zealand Pharma US, Inc.2$40
Kvk-tech, Inc.3$37
Neurocrine Biosciences, Inc.1$36
Senseonics, Incorporated3$36
Novartis2$34
Intuity Medical Inc2$34
Vivus LLC2$32
Kyowa Kirin, Inc.1$30
Kowa Pharmaceuticals America, Inc.2$30
Bayer1$29
Vistapharm, Inc.2$27
GRT US Holding, Inc.3$27
Halozyme Inc1$18
Therapeuticsmd, Inc.1$16
Lifescan, Inc.1$16
Regeneron Healthcare Solutions, Inc.1$15
Eisai Inc.1$15
Vertical Pharmaceuticals, LLC1$14
Johnson & Johnson1$11
Currax Pharmaceuticals LLC1$10

How this compares

$3,226,672 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$56,415
Medicare patients
179
Services billed
709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →